President-elect Donald Trump's nomination of Robert F. Kennedy Jr. to lead the Department of Health and Human Services is one of several unorthodox appointments rolled out in recent weeks, and ...
Hosted on MSN16h
Biocurious: From drug prices to efficiency drives, ASX biotechs await the ‘Trumpcare’ health falloutDonald Trump's appointment of Robert F Kennedy Junior as health czar means interesting times for US-focused ASX life sciences ...
Bavarian Nordic, with a diverse vaccine portfolio and $340 million in contracts for 2025, offers growth potential for ...
U.S. stocks are ticking higher as Wall Street recovers some of last week’s sharp slide. The S&P 500 rose 0.3% in afternoon ...
We recently compiled a list of the Jim Cramer Talked About These 11 Stocks Recently. In this article, we are going to take a ...
Robert F. Kennedy Jr.'s nomination to lead HHS is causing cautious concern among investors. Here's which companies and stocks ...
Moderna plans to prioritize new product approvals and oncology investments, as political concerns over Robert F. Kennedy Jr.'s HHS nomination weigh on vaccine stocks.
In a report released on November 15, Jason Gerberry from Bank of America Securities maintained a Buy rating on Vaxcyte (PCVX – Research ...
High-yield dividend stocks have been gaining momentum ahead of potential Fed rate cuts. While sticky inflation and possible ...
Many scientists at the federal health agencies await the second Donald Trump administration with dread as well as uncertainty ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback